Vivos Therapeutics (Vivos Therapeutics) Additional Paid-In Capital : $97.40 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics Additional Paid-In Capital?

Vivos Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 ($88.84 Mil) to Dec. 2023 ($93.46 Mil) and increased from Dec. 2023 ($93.46 Mil) to Mar. 2024 ($97.40 Mil).

Vivos Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($81.16 Mil) to Dec. 2022 ($84.27 Mil) and increased from Dec. 2022 ($84.27 Mil) to Dec. 2023 ($93.46 Mil).

Vivos Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Vivos Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics Additional Paid-In Capital Chart

Vivos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

20.33

52.25

81.16

84.27

93.46

Vivos Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															88.16	88.80	88.84	93.46	97.40

Vivos Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Vivos Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos Therapeutics (Vivos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120

Website

https://www.vivos.com

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.

Executives

Ronald Kirk Huntsman	director, 10 percent owner, officer: Chairman & CEO	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman	officer: Chief Financial Officer	6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow	director	REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson	director	2 MUSICK, IRVINE CA 92618
Anja B Krammer	director	C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh	director, 10 percent owner, officer: Chief Medical Officer	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129